BNP Paribas Call 80 NOVN 19.12.20.../ DE000PC394G4 /

2024-05-24 4:21:05 PM	Chg.-0.120	Bid5:19:49 PM	Ask5:19:49 PM	Underlying	Strike price	Expiration date	Option type
1.490EUR	-7.45%	- Bid Size: -	- Ask Size: -	NOVARTIS N	80.00 CHF	2025-12-19	Call

TeleTrader 05-02 Novartis to acquire Mariana Oncology for $1.7B

TeleTrader 04-23 Novartis up 5% on upbeat guidance, earnings

TeleTrader 04-23 Novartis EPS up 28% to $1.31 in Q1

GlobeNewswire 04-16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...

TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share

TeleTrader 04-09 Novartis to reduce workforce by 680 in Product Development

GlobeNewswire 03-14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon

TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal

GlobeNewswire 02-28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B

TeleTrader 01-31 Novartis net sales up 8% to $11.4B in Q4

GlobeNewswire 01-10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...

GlobeNewswire 01-05 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...

GlobeNewswire 01-02 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...

GlobeNewswire 2023-12-21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...

GlobeNewswire 2023-12-19 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...

GlobeNewswire 2023-12-11 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...

GlobeNewswire 2023-12-08 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...

GlobeNewswire 2023-12-06 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...

TeleTrader 2023-11-28 Novartis expects 5% annual sales growth until 2027

GlobeNewswire 2023-11-20 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH

TeleTrader 2023-10-24 Novartis Q3 EPS up 20% to $0.73

GlobeNewswire 2023-10-19 Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search

GlobeNewswire 2023-10-10 Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

TeleTrader 2023-10-04 Sandoz seals spin-off from Novartis, starts trading